-
Mashup Score: 1Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis - 17 hour(s) ago
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis - 13 day(s) ago
Improvements in the 4 hallmarks of myelofibrosis were observed with pelabresib plus ruxolitinib vs placebo plus ruxolitinib in JAK inhibitor-naive disease.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet-
Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis @ASH_hematology #ASH24 #heme #oncology #MedEd #MedTwitter https://t.co/h0d8bQt6wf
-
Pelabresib Plus Ruxolitinib Leads to Sustained Responses in JAK Inhibitor-Naive Myelofibrosis @ASH_hematology #ASH24 #heme #oncology #MedEd #MedTwitter https://t.co/h0d8bQt6wf